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Abstract. We tested Tankyrase-1 mRNA expression in colon
cancer patients to evaluate the prognostic role of this para-
meter by real-time RT-PCR in a retrospective group of 82
unselected patients with colon cancer. Paired cancer and
corresponding not affected tissues were used. Laser-assisted
microdissection was used to measure Tankyrase-1 mRNA in
homogeneous cancer cell populations and in normal colon
epithelium of the same patients. Tankyrase-1 mRNA in colon
cancers, as a mean, was significantly higher than in paired not
affected tissues (p<0.0001), but its level correlates inversely
with a cancer progression stage. Survival analysis indicated
that lower Tankyrase-1 mRNA expression in colon cancers was
significantly associated to reduced patient survival (p=0.019)
and disease-free interval (p=0.035), confirmed also in a multi-
variate analysis.
Introduction
The morphologic and molecular events of colon cancer occur
via a multistep pathway (1). A number of histopathological
studies indicate that the majority of colorectal tumors arise
from adenomatous polyps, with a progression of the small
adenoma to a larger lesion and subsequently to a carcinoma
(2). By molecular genetic studies considerable advances in the
molecular understanding of colorectal cancer have been
made with the identification of mutations of the adenomatous
polyposis coli gene, 5q chromosomal mutations, ras oncogene
expression, deletion of chromosome 18 and allelic loss of
DCC and p53, mutational activation of oncogenes, deletion and
allelic loss (3). Another important step of colorectal carcino-
genesis of colon tumors is the acquisition of immortality.
Telomeres and its associated proteins have been shown to be
involved in the control of cell proliferation, in the regulation
of cell senescence in most somatic cells, and in the unlimited
proliferation of malignant cells (4).
Tumor cells need to compensate for replicative telomere
losses to preserve their ability to proliferate indefinitely (5,6).
The extensive proliferation of cell during the prolonged
multistep tumorigenesis pathway is predicted to exhaust the
telomere reserve, necessitating telomerase activation (6-12).
Telomere stability is believed to be accomplished by the action
of other telomere-specific binding proteins. The enzyme
Tankyrase-1, a telomeric poly(ADP-ribose) polymerase
(PARP), was identified as a component of the human telomeric
complex (13). PARPs catalyze formation of long chains of
poly(ADP-ribose) onto protein acceptors using NAD+ as a
substrate. Tankyrase-1 interacts with the telomeric DNA-
binding protein TRF1 (TTAGGG repeat binding factor 1)
(14), a negative regulator of telomere length (13,15-17). TRF1
is believed to act in cis at telomeres to regulate access of
telomerase counteracting telomerase-mediated telomere
elongation. Tankyrase-1 seems to inhibit TRF1 binding to
telomeres through the Tankyrase-mediated ADP-ribosylation
of TRF1 protein (13). Overexpression of Tankyrase-1 in the
nucleus releases TRF1 from telomeres and induces telomere
elongation indicating Tankyrase-1 as a positive regulator
of telomere length. Unlike telomerase, the expression of
Tankyrase-1 would be expected ubiquitously distributed in all
somatic cells but its expression is expected to be upregulated
in all human tumors. Recent evidence confirmed this role also
in vivo (18) reporting an increase of Tankyrase-1 expression
in multiple myeloma and plasma cell leukemia and this
upregulation was concomitant to the expression of human
telomerase reverse transcriptase (hTERT) and telomerase
RNA template (hTER) (19). Similar results were reported in
patients with high-grade non-Hodgkins's lymphomas (20)
and with breast cancers (21).
The aim of this study was to evaluate the level of mRNA
expression of the Tankyrase-1 gene by real-time PCR in
colorectal cancers and in adjacent normal tissues. Micro-
dissection experiments contributed to clarify Tankyrase-1
mRNA distribution in normal colon epithelium.
Patients and methods
Tissues were obtained from 82 patients with sporadic
colorectal carcinoma (48 males and 34 females, age range:
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48-89 years, mean = 66.9), scheduled for elective resection.
Informed consent was previously obtained from all patients.
For all of them at least one sample of both neoplastic and
normal tissue (taken 10 cm apart from the neoplasm) were
collected at surgery. Samples were immediately snap-frozen
and stored in liquid nitrogen. Tumor was localized in the
right colon in 32 patients, in the left colon in 28 patients (8 in
the descending, and 20 in the sigmoid colon), and in the
rectal portion in the remaining 22 patients. Histological
examination was performed routinely in all cases. An adequate
number of sections were sampled from each tumor. Slides
were reviewed by the same pathologist without knowledge of
real-time results. Tumor histotype and grade of differentiation
were defined according to the World Health Organization
criteria (22). The pattern of cancer growth was defined as
expanding (when the tumor border was clearly demarcated;
n=32) and as infiltrating (when cancer cells spread into the
surrounding tissues without a distinct border; n=50) (23). All
cases were staged according to the original Dukes' system:
Dukes A=13; Dukes B=39, Dukes C=22 and Dukes D=8,
respectively. According to the histopathological grading, 10
tumors were G1, 46 were G2, 4 were G3 and 12 were colloid;
the other 4 showed a mixed pattern of G2 plus colloid. Six
were in situ tumors. All patients received a comparable post-
surgical therapy. The median follow-up for this group of
patients was 43.8 months (maximum 64.6 months).
Total RNA from cancer and normal tissues was extracted
with the RNeasy mini reagent kit (Qiagen, Milan, Italy),
according to the manufacturer's recommendations. Total
RNA (400 ng) was reverse transcribed using TaqMan RT PCR
kit (PE Applied Biosystems, Forster City, CA, USA). Reverse
transcription was performed in a final volume of 80 μl
containing 500 mM KCl, 0.1 mM EDTA, 100 mM Tris-HCl,
pH 8.3, 5.5 mM MgCl2, 500 μM of each dNTP, 2.5 μM of
random examers, 0.4 U/μl of RNase inhibitor, 1.25 U/μl of
Multiscribe Reverse Transcriptase according to the manu-
facturer's recommendations. Total RNA, isolated from DU145
cell line (human prostate cancer ATCC HTB 81) was used to
generate a standard curve for the TaqMan assay. This cell line
was chosen for the relative high expression of Tankyrase-1
mRNA expression.
Real-time RT-PCR. The primers and probe for the measure-
ment of Tankyrase-1 mRNA expression were selected by the
proprietary software ‘primer express’ (PE Applied Biosystems).
The forward primer 5'-ATGCCCCCAGAGGCCTTAC-3'
(2871-2879), reverse primer 5'-GGTGGATGCTGGTGA
GATCA-3' (2932-2951) and fluorescent probe (FAM) 5'-CT
GTTTTAAACCTCAGGCTACTGTAGTGAGTGCCT-3'
(2894-2928) were obtained from the Tankyrase-1 gene
sequence AF082556 (GenBank). Since other Tankyrase-1-
related genes kave also been identified and cloned (24), we
tested the specificity of our primers and probe for Tankyrase-1
mRNA using the ExPASy program, as previously reported
(21). In each sample the presence of GAPDH mRNA
expression was also tested with the commercial kit GAPDH
control reagent (PE Applied Biosystems) to exclude RNA
degradation.
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Figure 1. Example of laser-assisted microdissection of colon cancer (panel D) and paired not affected normal epithelia collected 10 cm apart from neoplastic
lesion. In normal crypt three different areas were selected corresponding to the fondus (panel A), mainly composed by active proliferating cells, the medium
part of the crypt wall (panel B) and superficial luminal cells (panel C). The microdissected area is indicated in panel 1, while in panel 2 the fragment
catapulted after dissection is reported. Mean results of Tankyrase-1 mRNA/cell from six experiments are graphically reported in panel E.
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The expression of Tankyrase-1 was calculated by referring
to an external reference curve generated with total RNA
extracted from the human prostate carcinoma DU145 cell line
(from 25 ng to 2.5 pg of cDNA), overexpressing Tankyrase-1
mRNA. For each sample 25 ng of cDNA were added to 25 μl
of PCR mix containing 300 nM of each primer, 1X Universal
master mix (PE Applied Biosystem) and 100 nM of a
fluorescent specific probe. The samples and the standards were
then subjected to 40 cycles of amplification at 95˚C for 15 sec
and 60˚C for 60 sec in the ABI Prism 7700 sequence detector
(PE Applied Biosystems). The results were expressed in terms
of equivalents of ng DU145 RNA/μg total RNA.
Laser-assisted microdissection. Microdissection experiments
were performed in a limited number of paired cancer and not
affected tissues (n=6), to measure Tankyrase-1 mRNA in
homogeneous clusters of colon cancer cells but also in basal
compartment of intestinal cripts, in the medium of the cript
and superficial luminal cells, all taken at ~10 cm from the
neoplastic lesion and expected to be not affected (Fig. 1). For
microdissection we used the PALM laser-microbeam system
(P.A.L.M. Microlaser Technologies AG, Bernried, Germany)
which enables the contact-free isolation of single cells or
group of cells. The sections were mounted onto a polyethylene
naphthalate membrane slide according to the manufacturer's
instructions. Frozen section were fixed with ethanol
immediately after cutting in a cryostat, stained with H&E
followed by increasing ethanol series and air dried. The
microdissected cells were catapulted into the lid of a 0.5-ml
reaction tube containing 5 μl of catapult buffer (20 mmol/l
Tris pH 8.0; 2 mmol/l EDTA; 0.5% Igepal CA-630 (Sigma-
Aldrich, Milan, Italy) by means of the laser pressure catapulting
technique of the instrument. RNeasy micro kit (Qiagen) was
used for total RNA purification from the microdissected
samples following the manufacturer's procedure for micro-
dissected cryosections (RNeasy Micro Handbook 4/2003). A
volume of 12 μl of RNA solution was recovered after the
elution step. Of the total RNA sample, 9 μl were reverse-
transcribed in a final volume of 20 μl. The cDNA sample (5 μl)
was used for real-time PCR amplification. Values of
Tankyrase-1 mRNA expression were corrected on the basis
of the theoretical number of cells contained in the micro-
dissected sample (n. cells = microdissected area μm2/500 μm2).
Statistical analyses. Statistical analysis was carried out using
the SPSS software package (SPSS Inc., Chicago, IL). Statistical
differences between groups were assessed by t-test analysis.
For analysis of follow-up data, life table curves were calculated
using the Kaplan-Meier method and survival distribution were
comparated by log-rank statistics. The primary end point was
cancer-related survival, as measured from the date of surgery
to the time of last follow-up or cancer-related death. The
joint effects with other variables were examined via Cox
proportional hazard analysis. Differences were considered
statistically significant at p<0.05.
Results
Quantitative RT-PCR. Tankyrase-1 mRNA was expressed in
100% tumor samples and paired not affected tissues. The
level of this expression was quite variable, ranging from 0.1
to 1210 ng DU145 RNA/μg total RNA for cancers and from
0.02 to 524 for paired unaffected samples, respectively. In
61/82 (74%) of the paired samples, the expression in tumor
was higher (at list twice) than in corresponding normal tissue
and the mean levels of mRNA were significantly higher
(p<0.0001) in cancer samples (112.5±21.3 ng) than in
corresponding normal counterparts (49.6±9.6), with a mean
cancer/normal tissue ratio of 8.9±2.0.
Laser microdissection. In six random patients the laser
dissected area was isolated in colon cancers. The peripheral
zone of the tumor was chosed to prevent contamination by
internal necrotic areas. In the same patients we isolated
fragments of normal epithelium corresponding to the basal
compartment of the crypts, the medium portion of crypt wall
and the superficial luminal epithelium, according to the scheme
reported in Fig. 1. Tankyrase-1 per cell mRNA espression
was then calculated after correction with dissected area
surface and mean cell diameter evaluation. Tankyrase-1
mRNA expression decreases consistently from the basal
compartment to the superficial epithelium, whereas the
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Figure 2. Cumulative cancer-related survival (left panel) and disease-free interval (right panel) in patients with high Tankyrase-1 mRNA expression (>44 ng
DU145 RNA/μg total RNA) compared to patients with low Tankyrase-1 mRNA expression (≤44 ng DU145 RNA/μg total RNA). Survival distributions were
calculated using the Kaplan-Meier method and compared by log-rank analysis.
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espression in cancer samples is superimposable to that found
in basal proliferating fondus of colon crypts (Fig. 1).
Tankyrase-1 mRNA and clinicopathological features. Table I
shows the mean values of absolute expression of Tankyrase-1
mRNA in colon cancers and the ratio between cancers and
normal tissues, stratified according to the clinicopatho-
logical features of our patients. Tankyrase-1 mRNA was
significantly higher (p=0.041) in tumors with an expanding
growth in comparison to cancer with an infiltrating pattern. A
reduction of mRNA levels, although not statistically proven,
appears constantly associated to more advanced cancers, as
in Dukes C-D, in G2-G3, in metastatic cancers and in patients
with high pre-operative CEA (>5 ng/ml). This tendency to a
reduction of Tankyrase-1 expression in more advanced colon
cancer was confirmed by the ratio of Tankyrase-1 expression
between cancers and not affected tissues. The ratio was
consistently reduced in low grade cancers, in N+ or metastatic
patients. The ratio was reduced to 1/3 in patients with high
CEA pre-operative concentrations, in subjects <55 years old
and in females.
Survival analyses. The median follow-up duration of our
patients was 43.8 months. Patients were stratified according
to the median level of Tankyrase-1 mRNA expression (44 ng
DU145 RNA/μg total RNA). Survival analysis of cancer-
related death was obtained by comparing patients with high
Tankyrase-1 mRNA (> median value) versus those with low
expression (≤ median value). According to this division, we
found that patients with lower levels of mRNA had a
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Expression in cancer tissuea Cancer/normal ratio
––––––––––––––––––––––––––––––––––––––– –––––––––––––––––––––––––
n Mean ± SE p Mean ± SE p
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Age
<55 years 6 87.8±34.6 2.1±1.1
≥55 years 76 114.4±22.7 0.746 9.3±2.2 0.006
Gender
Male 48 107.8±30.5 12.0±3.3
Female 34 119.1±28.1 0.795 4.2±1.1 0.032
Localization 
Right 32 135.97±44.26 6.5±2.4
Left 50 97.54±20.45 0.381 10.3±3.0 0.320
Pattern of growth
Infiltrating 50 71.0±11.0 9.2±3.1
expanding 32 189.5±54.2 0.041 7.4±2.7 0.678
Dukes
A-B 52 126.4±31.6 8.9±2.0
C-D 30 88.4±18.7 0.391 8.8±4.5 0.980
Grading
G0/G1 17 170.7±50.5 10.3±3.6
G2/G3 65 93.1±24.8 0.147 7.9±2.6 0.633
Lymph nodes
Negative 55 114.2±33.6 10.7±2.8
Positive 27 112.2±30.9 0.964 5.5±2.7 0.190
Metastasis
Negative 73 118.8±23.6 9.5±2.3
Positive 9 61.5±18.6 0.403 4.1±2.8 0.155
CEA
<5 ng/ml 54 124.9±30.0 12.0±3.2
≥5 ng/ml 28 94.6±30.6 0.526 4.0±1.4 0.264
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aResults are expressed in terms of ng DU145 RNA/μg total RNA.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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significantly reduced overall survival (log-rank test, p=0.019)
and a shorter disease-free survival (p=0.035) (Fig. 2).
A multivariate analysis was performed to evaluate whether
the correlation between low Tankyrase expression and
shortened cancer-related survival resulted from an association
with other prognostically relevant factors. We found that low
Tankyrase-1 mRNA expression, Dukes' stage (A-B versus
C-D) and growth pattern (expanding vs. infiltrating),
correlated significantly with overall survival in univariate Cox
regression. Multivariate analysis demonstrated that high
Tankyrase-1 expression was a significant and independent
prognostic para-meter for shortened cancer-related survival in
our patients (p=0.025). The relative risk for cancer-related
death was 5.8-fold increased in case of low Tankyrase-1
mRNA (Table II).
Discussion
It is evident that telomere maintenance has a pivotal role in
the process of immortalization, chromosomal stability and
tumorigenesis in humans (25). The upregulation or reactivation
of a large number of factors maintaining telomere length
appears as precocious events in cell transformation. The
enzyme Tankyrase-1 was identified as a component of the
human telomeric complex acting as a positive regulator of
telomere length (13). This feature was confirmed in vivo (18).
Tankyrase-1 is upregulated in multiple myeloma, plasma cell
leukemia and high-grade non-Hodgkin's lymphomas (20-26);
on the contrary, other authors failed to find Tankyrase-1
overexpression in gastric cancers (27,28). In a very recent
study, it was demonstrated that Tankyrase-1 up-regulation
lessens the impact of telomerase inhibitors in vitro and that
inhibition of Tankyrase-1 PARP activity restores telomerase
shortening (29). These findings open new avenues in the
assessment of combined antitumoral therapies to decrease
telomere maintenance in cancer cells.
In a previous study we demonstrated that mRNA expression
of Tankyrase-1 was up-regulated in breast cancer (21). Herein,
we evaluated the expression of Tankyrase-1 mRNA in colon
cancers and in corresponding apparent normal tissues.
Tankyrase-1 mRNA was expressed in all samples and its
expression was significantly higher in tumors in comparison
to the corresponding normal adjacent samples. Interestingly,
the level of expression of Tankyrase-1 mRNA in colon cancer
is, as a mean, about twice higher than in breast cancer.
However, the mean increase of Tankyrase-1 mRNA in colon
cancer, expressed as cancer/normal tissue ratio was very low
(8.9±2.0) in comparison to the equivalent ratio in breast
cancers (327.6±205.5) (21). This finding seems to indicate
that, at least as a quantitative aspect, the up-regulation of
Tankyrase-1 mRNA in colon cancer seems less evident
and/or relevant.
To clarify the real entity of difference in Tankyrase-1
mRNA between normal and cancer tissue, we performed
microdissection experiments to detect the expression of
Tankyrase-1 in isolated colon cancer cells as well as in
normal epithelial cells collected in apparently normal colon
crypts, 10 cm apart from the neoplasia. As expected, on the
basis of the proposed role of Tankyrase-1 in maintaining
telomere length, the maximal expression in normal crypts
was found in the basal and proliferanting compartment of
colonic crypt. The expression of Tankyrase-1 mRNA seems to
decrease in the median and superficial compartment,
paralleling the progression and differentiation of the same
epithelial cells. Interestingly, the expression of Tankyrase-1
mRNA in microdissected cancer cells is higher than in
normal not-proliferating epithelial cells, but not statistacally
different from the expression of the basal compartment in
normal colon crypts.
Absolute Tankyrase-1 mRNA expression had limited
correlations with clinical and pathological features of our
patients, even if a tendency to the reduction of mRNA appears
constantly associated to more advanced cancers. Besides the
absolute expression of Tankyrase-1, we also evaluated the
ratio between cancer and paired not affected tissue. In our
opinion, this method is the best approach to evaluate the
levels of mRNA up-regulation for candidate genes in cancer
samples, even if differences in cellular composition between
colon cancer and paired normal tissue must be kept in mind.
The ratio confirmed that more advanced colon cancers tend
to reduce their Tankyrase-1 expression. This reduction was
significant in younger patients (<55) and in female patients.
Another finding supporting that the reduction of
Tankyrase-1 expression is connected to cancer progression
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Table II. Univariate and multivariate Cox regression analysis for 82 patients with resected colon carcinoma.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Univariate analysis Multivariate analysis
––––––––––––––––– ––––––––––––––––––––––––––––––––––––––––––––––––––
Variable p p Relative Risk Exp(B) Exp(B) 95% Cl
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Pattern of growth
Infiltrating vs. expanding 0.048 0.114 0.179 0.021-1.511
Dukes' stage
A+B vs. D+C 0.022 0.283 2.123 0.537-8.395
Tankyrase-1 mRNAa
High vs. low expression 0.037 0.027 5.875 1.225-28.174
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aSurvival analysis of cancer-related death was obtained by comparing patients with high Tankyrase-1 mRNA (> median value: i.e., >44 ng
DU145 RNA equivalents/μg total RNA) versus those with low expression (≤ median value).
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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was the prognostic value of this parameter. Reduced levels of
mRNA were associated to reduced patient survival and
disease-free interval. Tankyrase-1 mRNA prognostic value
was then confirmed in a multivariate analysis.
These data seem to indicate that the up-regulation of
Tankyrase-1 in colon cancer cells is quantitatively less evident
than in other human cancers (i.e. breast carcinoma) and not
higher than in normally proliferating cells from the same
tissue. The apparent association of reduced expression of
Tankyrase-1 in more advanced colon cancer seems to indicate
that the up-regulation of this gene takes place only during the
first phases of cancer progression, when the need of
stabilizing telomeres might be maximal. In more advanced
cancers, other mechanisms than Tankyrase-1 expression may
be more relevant in cell immortalization and telomere
maintainance.
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